Covered recipient · General Payments record
PABLO F MORA
Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$77,886.46
180 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $58,165.40 | 39 |
| Consulting Fee | $14,227.30 | 8 |
| Food and Beverage | $2,928.97 | 115 |
| Travel and Lodging | $2,532.52 | 17 |
| Education | $32.27 | 1 |
By paying entity
PY2020 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk Inc | $56,085.75 | 58 |
| Mannkind Corporation | $11,118.47 | 33 |
| Dexcom, Inc. | $5,778.13 | 18 |
| Tandem Diabetes Care, Inc. | $2,550.00 | 9 |
| Janssen Pharmaceuticals, Inc | $744.55 | 3 |
| Novartis Pharmaceuticals Corporation | $471.55 | 4 |
| Amarin Pharma Inc. | $254.63 | 8 |
| Xeris Pharmaceuticals, Inc. | $201.78 | 10 |
| AstraZeneca Pharmaceuticals LP | $186.84 | 10 |
| Merck Sharp & Dohme Corporation | $118.24 | 7 |
| Eli Lilly and Company | $84.67 | 1 |
| Lilly USA, LLC | $83.84 | 6 |
| Esperion Therapeutics, Inc. | $56.13 | 3 |
| Insulet Corporation | $44.82 | 3 |
| Medtronic MiniMed, Inc. | $36.23 | 3 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $21.87 | 1 |
| Amgen Inc. | $19.41 | 1 |
| SANOFI-AVENTIS U.S. LLC | $16.00 | 1 |
| Corcept Therapeutics | $13.55 | 1 |
Page 2 of 4; records 51–100 of 180 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
PABLO F MORA
NPI 1306836168 · CMS profile ID 149702
Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism
DALLAS, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 4; records 51–100 of 180 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1306836168?year=2020&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- PABLO F MORA, NPI 1306836168, CMS profile ID 149702. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 180 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1306836168?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). PABLO F MORA, NPI 1306836168, CMS profile ID 149702. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 180 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1306836168?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- PABLO F MORA, NPI 1306836168, CMS profile ID 149702, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 180 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1306836168?year=2020&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
180 matching records · $77,886.46 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 180.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Mannkind Corporation | $5.38 | 10/13/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 752675941 | CMS |
| Novo Nordisk Inc | $20.00 | 10/12/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744943865 | CMS |
| Mannkind Corporation | $17.63 | 10/07/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 752675939 | CMS |
| Dexcom, Inc. | $8.34 | 10/06/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 752068993 | CMS |
| Novo Nordisk Inc | $311.10 | 10/05/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 745066175 | CMS |
| Novo Nordisk Inc | $48.68 | 09/30/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744992053 | CMS |
| Novo Nordisk Inc | $2,379.00 | 09/30/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744992055 | CMS |
| Dexcom, Inc. | $1,200.00 | 09/24/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 752068991 | CMS |
| Novo Nordisk Inc | $8.62 | 09/24/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744992051 | CMS |
| Dexcom, Inc. | $7.20 | 09/16/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 752068989 | CMS |
| Mannkind Corporation | $10.11 | 09/15/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 752675937 | CMS |
| Novo Nordisk Inc | $6.29 | 09/15/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744886685 | CMS |
| AstraZeneca Pharmaceuticals LP | $23.20 | 09/11/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 736203147 | CMS |
| Amarin Pharma Inc. | $21.33 | 09/09/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 739979963 | CMS |
| AstraZeneca Pharmaceuticals LP | $22.80 | 09/01/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 735786445 | CMS |
| Xeris Pharmaceuticals, Inc. | $19.47 | 08/31/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 739716355 | CMS |
| Novo Nordisk Inc | $1,262.70 | 08/27/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744879409 | CMS |
| Novo Nordisk Inc | $1,683.60 | 08/27/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744879419 | CMS |
| Mannkind Corporation | $22.11 | 08/24/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 752675935 | CMS |
| Amarin Pharma Inc. | $6.63 | 08/19/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 739993483 | CMS |
| Mannkind Corporation | $9.93 | 08/19/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 752675933 | CMS |
| Novo Nordisk Inc | $1,830.00 | 08/19/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744979623 | CMS |
| Novo Nordisk Inc | $17.47 | 08/18/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744842313 | CMS |
| Novo Nordisk Inc | $0.86 | 08/18/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744842315 | CMS |
| Novo Nordisk Inc | $1,830.00 | 08/18/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744974801 | CMS |
| Novo Nordisk Inc | $1,830.00 | 08/18/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744976493 | CMS |
| Novo Nordisk Inc | $1,830.00 | 08/18/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744978359 | CMS |
| Novo Nordisk Inc | $2,379.00 | 08/18/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744979501 | CMS |
| Novo Nordisk Inc | $116.04 | 08/18/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744979503 | CMS |
| Novo Nordisk Inc | $29.38 | 08/18/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744979517 | CMS |
| Novo Nordisk Inc | $1,830.00 | 08/18/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744991453 | CMS |
| Novo Nordisk Inc | $1,830.00 | 08/14/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 745055027 | CMS |
| Lilly USA, LLC | $12.69 | 08/13/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728598023 | CMS |
| Novo Nordisk Inc | $1,830.00 | 08/13/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744878779 | CMS |
| Merck Sharp & Dohme Corporation | $15.27 | 08/11/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747691411 | CMS |
| Dexcom, Inc. | $1,200.00 | 08/06/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 752068987 | CMS |
| Novo Nordisk Inc | $22.86 | 08/05/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744825277 | CMS |
| Mannkind Corporation | $9.33 | 07/28/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 752675931 | CMS |
| Xeris Pharmaceuticals, Inc. | $23.79 | 07/27/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 739716353 | CMS |
| Mannkind Corporation | $5.64 | 07/22/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 752675927 | CMS |
| Mannkind Corporation | $14.09 | 07/22/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 752675929 | CMS |
| Novo Nordisk Inc | $13.79 | 07/21/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744797099 | CMS |
| Mannkind Corporation | $7.06 | 07/15/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 752675925 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.60 | 07/14/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 736152879 | CMS |
| Merck Sharp & Dohme Corporation | $20.25 | 07/13/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747716811 | CMS |
| Novo Nordisk Inc | $1,830.00 | 07/09/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744878239 | CMS |
| Novo Nordisk Inc | $15.55 | 07/08/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744780551 | CMS |
| Amarin Pharma Inc. | $19.60 | 07/07/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 739993481 | CMS |
| Dexcom, Inc. | $11.94 | 07/01/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 752068985 | CMS |
| Mannkind Corporation | $1,125.00 | 06/29/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 752675923 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $366,051.79 | 23 |
| PY2024 | Recipient | $1,563.06 | 11 |
| PY2024 | Principal investigator | $153,239.24 | 24 |
| PY2023 | Principal investigator | $6,859.80 | 2 |
| PY2020 | Recipient | $145.50 | 1 |
| PY2020 | Principal investigator | $107,900.03 | 116 |
| PY2019 | Recipient | $8,403.48 | 4 |
| PY2019 | Principal investigator | $169,054.20 | 51 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
23 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $5,520.00 | 12/31/2025 | Non-covered Recipient Entity TEKTON RESEARCH | A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism | No dispute reported | 06/30/2026 | 1202534639 |
| Principal investigator 1 | ABBVIE INC. | $5,814.45 | 12/31/2025 | Non-covered Recipient Entity TEKTON RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202535387 |
| Principal investigator 1 | ABBVIE INC. | $19,448.10 | 11/05/2025 | Non-covered Recipient Entity TEKTON RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202522201 |
| Principal investigator 1 | ABBVIE INC. | $16,580.70 | 10/09/2025 | Non-covered Recipient Entity TEKTON RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202515339 |
| Principal investigator 1 | ABBVIE INC. | $14,380.20 | 09/04/2025 | Non-covered Recipient Entity TEKTON RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202509138 |
| Principal investigator 1 | ABBVIE INC. | $18,909.45 | 08/06/2025 | Non-covered Recipient Entity TEKTON RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202503069 |
| Principal investigator 1 | Amgen Inc. | $8,025.84 | 08/01/2025 | Non-covered Recipient Entity TEKTON RESEARCH LLC | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2) | No dispute reported | 06/30/2026 | 1246649065 |
| Principal investigator 1 | ABBVIE INC. | $395.80 | 07/31/2025 | Non-covered Recipient Entity TEKTON RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202500570 |
| Principal investigator 1 | ABBVIE INC. | $16,046.10 | 07/02/2025 | Non-covered Recipient Entity TEKTON RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202494141 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $23,689.00 | 07/02/2025 | Non-covered Recipient Entity Tekton Research Inc | A 52-week Randomized, Double-blind, Placebo-controlled, Multi-center Phase 2a Study Assessing Safety and Efficacy of SAR442970, a Dual Anti-TNF and Anti-OX40L NANOBODY Molecule, for Preservation of Pancreatic B-cell Function in Adults and Adolescents With Recently Diagnosed Type 1 Diabetes | No dispute reported | 06/30/2026 | 1226108276 |
| Principal investigator 1 | Medtronic, Inc. | $1,560.00 | 06/24/2025 | Non-covered Recipient Entity Tekton Research | CIP341 IMPACT2 | No dispute reported | 06/30/2026 | 1192327470 |
| Principal investigator 1 | Medtronic, Inc. | $3,500.00 | 06/17/2025 | Non-covered Recipient Entity Tekton Research | CIP341 IMPACT2 | No dispute reported | 06/30/2026 | 1192327468 |
| Principal investigator 1 | ABBVIE INC. | $27,603.45 | 06/03/2025 | Non-covered Recipient Entity TEKTON RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202488735 |
| Principal investigator 1 | Medtronic, Inc. | $5,000.00 | 05/23/2025 | Non-covered Recipient Entity Tekton Research | CIP341 IMPACT2 | No dispute reported | 06/30/2026 | 1192327466 |
| Principal investigator 1 | ABBVIE INC. | $19,866.60 | 05/07/2025 | Non-covered Recipient Entity TEKTON RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202483815 |
| Principal investigator 1 | Eli Lilly and Company | $127,380.00 | 04/08/2025 | Non-covered Recipient Entity TEKTON RESEARCH INC | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY COMPARED TO PLACEBO IN ADULT PARTICIPANTS WITH TYPE 1 DIABETES AND OBESITY OR OVERWEIGHT (SURPASS-T1D-1) | No dispute reported | 06/30/2026 | 1187890108 |
| Principal investigator 1 | ABBVIE INC. | $10,597.50 | 04/03/2025 | Non-covered Recipient Entity TEKTON RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202472819 |
| Principal investigator 1 | ABBVIE INC. | $12,309.30 | 03/07/2025 | Non-covered Recipient Entity TEKTON RESEARCH LLC | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202459134 |
| Principal investigator 1 | Amgen Inc. | $13,464.70 | 02/25/2025 | Non-covered Recipient Entity TEKTON RESEARCH | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2) | No dispute reported | 06/30/2026 | 1246649100 |
| Principal investigator 1 | Medtronic, Inc. | $438.00 | 02/21/2025 | Non-covered Recipient Entity Tekton Research | CIP341 IMPACT2 | No dispute reported | 06/30/2026 | 1192327464 |
| Principal investigator 1 | Medtronic, Inc. | $57.00 | 02/11/2025 | Non-covered Recipient Entity Tekton Research | CIP341 IMPACT2 | No dispute reported | 06/30/2026 | 1192327462 |
| Principal investigator 1 | ABBVIE INC. | $14,385.60 | 02/06/2025 | Non-covered Recipient Entity TEKTON RESEARCH LLC | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202448612 |
| Principal investigator 1 | ABBVIE INC. | $1,080.00 | 01/02/2025 | Non-covered Recipient Entity TEKTON RESEARCH LLC | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202435031 |